Adhikari Rajan P, Kort Thomas, Shulenin Sergey, Kanipakala Tulasikumari, Ganjbaksh Nader, Roghmann Mary-Claire, Holtsberg Frederick W, Aman M Javad
Integrated Biotherapeutics Inc., Gaithersburg, Maryland, United States of America.
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; VA Maryland Health Care System, Baltimore, Maryland, United States of America.
PLoS One. 2015 Sep 14;10(9):e0137874. doi: 10.1371/journal.pone.0137874. eCollection 2015.
S. aureus vaccine development has proven particularly difficult. The conventional approach to achieve sterile immunity through opsonophagocytic killing has been largely unsuccessful. S. aureus is highly toxigenic and a great body of evidence suggests that a successful future vaccine for this organism should target extracellular toxins which are responsible for host tissue destruction and immunosuppression. Major staphylococcal toxins are alpha toxin (a single subunit hemolysin) along with a group of bicomponent pore-forming toxins (BCPFT), namely Panton-Valentine leukocidin (PVL), gamma hemolysins (HlgCB and AB), LukAB and LukED. In our previous report, an attenuated mutant of LukS-PV (PVL- S subunit) named as "LukS-mut9" elicited high immunogenic response as well as provided a significant protection in a mouse sepsis model. Recent discovery of PVL receptors shows that mice lack receptors for this toxin, thus the reported protection of mice with the PVL vaccine may relate to cross protective responses against other homologous toxins. This manuscript addresses this issue by demonstrating that polyclonal antibody generated by LukS-mut9 can neutralize other canonical and non-canonical leukotoxin pairs. In this report, we also demonstrated that several potent toxins can be created by non-canonical pairing of subunits. Out of 5 pairs of canonical and 8 pairs of non-canonical toxins tested, anti-LukS-mut9 polyclonal antibodies neutralized all except for LukAB. We also studied the potential hemolytic activities of canonical and noncanonical pairs among biocomponent toxins and discovered that a novel non-canonical pair consisting of HlgA and LukD is a highly toxic combination. This pair can lyse RBC from different species including human blood far better than alpha hemolysin. Moreover, to follow-up our last report, we explored the correlation between the levels of pre-existing antibodies to new sets of leukotoxins subunits and clinical outcomes in adult patients with S. aureus bacteremia. We found that there is an inversed correlation between the antibody titer to sepsis for leukotoxins LukS-mut9, LukF-PV, HlgC, LukE and LukAB, suggesting the risk of sepsis was significantly lower in the patients with higher antibody titer against those toxins.
金黄色葡萄球菌疫苗的研发已被证明极具难度。通过调理吞噬杀伤作用实现无菌免疫的传统方法在很大程度上并不成功。金黄色葡萄球菌具有高度毒性,大量证据表明,未来针对这种病原体的成功疫苗应靶向负责宿主组织破坏和免疫抑制的细胞外毒素。主要的葡萄球菌毒素是α毒素(一种单亚基溶血素)以及一组双组分成孔毒素(BCPFT),即杀白细胞素(PVL)、γ溶血素(HlgCB和AB)、LukAB和LukED。在我们之前的报告中,一种名为“LukS-mut9”的LukS-PV(PVL-S亚基)减毒突变体引发了高免疫原性反应,并在小鼠败血症模型中提供了显著保护。最近对PVL受体的发现表明,小鼠缺乏这种毒素的受体,因此报告的PVL疫苗对小鼠的保护作用可能与针对其他同源毒素的交叉保护反应有关。本手稿通过证明由LukS-mut9产生的多克隆抗体可以中和其他典型和非典型白细胞毒素对来解决这个问题。在本报告中,我们还证明了亚基的非典型配对可以产生几种强效毒素。在测试的5对典型毒素和8对非典型毒素中,抗LukS-mut9多克隆抗体除了LukAB外,中和了所有毒素。我们还研究了双组分毒素中典型和非典型对的潜在溶血活性,发现由HlgA和LukD组成的新型非典型对是一种剧毒组合。这一对毒素对包括人血在内的不同物种的红细胞的裂解能力远优于α溶血素。此外,为了跟进我们的上一份报告,我们探讨了成年金黄色葡萄球菌菌血症患者中针对新一组白细胞毒素亚基的预先存在抗体水平与临床结果之间的相关性。我们发现,针对白细胞毒素LukS-mut9、LukF-PV、HlgC、LukE和LukAB的败血症抗体滴度呈负相关,这表明针对这些毒素抗体滴度较高的患者败血症风险显著较低。